Replies to post #359595 on Anavex Life Sciences Corp (AVXL)

[Kb1123]

I’d say by end of Q2 next year we will have a pretty good idea on wether our investment will be successful or not. By this time next year we will either have filed an NDA for ReTT and Alz or not. If we have not and the FDA requires more trials we are looking at another 4 years of waiting for P3 trials to recruit and complete. Alzheimer readout this year will be a binary event likely causing the stock price to go to $2 or $50 based on the data. I don’t feel like there will be any medium ground. JMHO

[catdaddy]

You should sell!

[Trainguy1]

I think next month could be pivotal following completion and release of top line results for PDD OLE. If safety is confirmed, and dementia, sleep, & parkinsonian movement issues prove to be stablized or improved since the end of ph2 at least for patients with wild type sigma-1 receptors, then A2-73 may be acceptable for NDA submittal.

[tootalljones]